Although treatment for EGFR‐mutated NSCLC patients is actively being conducted in Korea, there is a lack of large‐scale, multicenter studies focusing on clinicopathologic datasets and real‐world treatment outcomes. Here, EGFR is linked to non-small cell lung carcinoma.